See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $335B | 5.2x | 11.2x | |
| $201B | 3.2x | 8.1x | |
| $138B | 3.2x | 9.4x | |
| $131B | 2.5x | 8.2x | |
| $60.7B | 3.6x | 10.5x | |
| $57.7B | 6.6x | 21.4x | |
| $16.4B | 8.6x | -5.1x | |
| $10.2B | 3.3x | -8.3x | |
| $9.9B | 89.6x | n/a | |
| $7.6B | 3.6x | -38.9x | |
| $7.6B | 7.7x | 24.9x | |
| $7.2B | n/a | -8.5x | |
| $6.9B | 23.0x | 541.1x | |
| $4.7B | 11.2x | 34.0x | |
| $3.6B | 5.2x | 13.9x | |
| $3.0B | n/a | n/a | |
| $2.6B | 7.1x | 24.6x | |
| $2.5B | 5.8x | 21.7x | |
| $2.4B | n/a | n/a | |
| $2.3B | n/a | n/a | |
| $2.3B | 5.2x | -81.9x | |
| $2.1B | 275.3x | -10.2x | |
| $2.0B | 2.1x | 5.8x | |
| $1.8B | 7.3x | -5.0x | |
| $1.8B | 40.6x | -11.8x | |
| $1.7B | 6.7x | 286.3x | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.4B | 542.8x | -5.4x | |
| $1.3B | 6.3x | -47.7x | |
| $1.2B | 6.5x | 17.7x | |
| $1.2B | n/a | n/a | |
| $1.2B | 39.5x | -32.8x | |
| $1.2B | n/a | n/a | |
| $1.1B | 1.1x | 3.0x | |
| $1.1B | 12.7x | -32.1x | |
| $1.0B | n/a | n/a | |
| $1.0B | 5.1x | -19.9x | |
| $929M | 5.8x | 12.3x | |
| $897M | 19.1x | -4.5x | |
| $860M | 41.4x | -1.7x | |
| $819M | n/a | n/a | |
| $793M | n/a | -10.3x | |
| $769M | 9.3x | -70.8x | |
| $693M | 3.7x | n/a | |
| $659M | n/a | n/a | |
| $594M | 106.1x | n/a | |
| $580M | n/a | n/a | |
| $468M | n/a | n/a | |
| $450M | 247329.4x | -2.2x | |
| $442M | 2.4x | 9.9x | |
| $439M | 348.9x | -1.4x | |
| $421M | n/a | n/a | |
| $420M | n/a | n/a | |
| $412M | n/a | -16.0x | |
| $394M | 7.8x | -7.1x | |
| $390M | n/a | n/a | |
| $380M | n/a | n/a | |
| $332M | n/a | n/a | |
| $323M | n/a | -1.9x | |
| $316M | n/a | n/a | |
| $302M | 27.6x | -7.7x | |
| $289M | n/a | n/a | |
| $255M | n/a | n/a | |
| $235M | 10451.3x | -1.4x | |
| $226M | n/a | n/a | |
| $219M | n/a | n/a | |
| $208M | n/a | -4.5x | |
| $198M | 69.6x | -10.4x | |
| $185M | n/a | -1.1x | |
| $165M | 137.1x | -3.4x | |
| $163M | 1.2x | n/a | |
| $162M | 4.9x | n/a | |
| $154M | 2.0x | -0.6x | |
| $136M | n/a | n/a | |
| $126M | n/a | n/a | |
| $116M | n/a | n/a | |
| $115M | n/a | n/a | |
| $113M | n/a | -4.5x | |
| $111M | 2.2x | -37.5x | |
| $108M | n/a | n/a | |
| $102M | n/a | n/a | |
| $99.5M | n/a | -3.6x | |
| $99.4M | 2.3x | -0.6x | |
| $98.9M | n/a | n/a | |
| $92.5M | n/a | n/a | |
| $90.3M | n/a | n/a | |
| $84.5M | n/a | n/a | |
| $84.0M | 16.8x | n/a | |
| $83.6M | 946.1x | n/a | |
| $80.6M | 11.1x | n/a | |
| $75.7M | 12.8x | n/a | |
| $68.9M | n/a | n/a | |
| $66.6M | 33.9x | n/a | |
| $66.2M | n/a | n/a | |
| $48.9M | 14.6x | -1.3x | |
| $48.8M | n/a | n/a | |
| $47.3M | n/a | n/a | |
| $45.7M | n/a | n/a | |
| $44.0M | 16.5x | -0.3x | |
| $42.8M | n/a | n/a | |
| $42.3M | 0.3x | 1.1x | |
| $41.1M | 38.8x | -1.4x | |
| $40.4M | n/a | n/a | |
| $34.5M | 5.3x | -0.3x | |
| $31.6M | n/a | n/a | |
| $28.7M | n/a | -0.8x | |
| $19.7M | n/a | n/a | |
| $13.4M | 1.8x | n/a | |
| $13.3M | 0.1x | n/a | |
| $12.6M | n/a | -0.2x | |
| $12.3M | n/a | n/a | |
| $8.8M | 6.2x | -0.5x | |
| $8.6M | n/a | n/a | |
| $7.9M | 118.6x | n/a | |
| $7.5M | 277.2x | n/a | |
| $7.1M | 2.3x | -0.5x | |
| $1.4M | 0.5x | n/a | |
| $0.9M | n/a | -0.0x | |
| $0.4M | 0.1x | n/a | |
| -$10.7M | -1.0x | n/a | |
| -$13.9M | n/a | n/a | |
| -$18.0M | -6.3x | n/a | |
| -$28.7M | -2.7x | 0.2x | |
| -$38.2M | n/a | n/a | |
| -$57.7M | n/a | n/a | |
| -$92.9M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies